Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 276.00
Bid: 271.00
Ask: 276.00
Change: -1.00 (-0.36%)
Spread: 5.00 (1.845%)
Open: 277.00
High: 280.00
Low: 274.00
Prev. Close: 277.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS: G4S Swings To Profit And Top Of FTSE 100

Wed, 13th Aug 2014 11:21

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Wednesday.
-------
FTSE 100 - WINNERS
-------
G4S, up 2.4%. The security company said it swung back to a profit in the first half of the year as revenue rose and it didn't repeat the write offs and impairments that weighed on last year's results. The company is undergoing a revamp which has included asset sales, restructuring of its UK and Ireland operations, and a focus on gaining new profitable contracts, particularly in emerging markets, is showing signs of paying off. The company swung to a pretax profit of GBP85 million in the six months to June 30, compared with a loss of GBP94 million a year earlier when it had booked GBP124 million of impairment charges after a review of its operations and a writedown on some unprofitable contracts.

Prudential, up 2.2%. The financial services group continues to be one of the big risers in the blue-chip index following its increase in its interim dividend by 15% to 11.19 pence on Tuesday.

Land Securities Group, up 1.6%. The property firm said it has sold its 50% stake in Cabot Circus shopping centres, Friars Quake and surrounding shops in Bristol to AXA Real Estate in a deal worth GBP267.8 million. The assets had produced net rental income of GBP17.3 million for Land Securities.

Petrofac, up 0.8%. The oil company said it has won a USD500 million contract from a subsidiary of Malaysia's national oil and gas company for a refinery package in the Pengerang project in Johor, Malaysia. The company said the engineering, procurement, construction and commissioning contract has been awarded by PRPC Refinery & Cracker Sdn Bhd, a subsidiary of Petroliam Nasional Berhad, known as Petronas. The Pengerang project is the largest liquid-based greenfield downstream scheme in Malaysia.
-------
FTSE 100 - LOSERS
-------
Admiral Group, down 4.5%. The non-life insurers lead the FTSE 100 fallers. Admiral reported a 2% rise in pretax profit but a 5% decline in revenues in its interim results. It also announced that Kevin Chedwick will replace Geraint Jones as the new chief financial officer, which according to Ben Vartia, trader at Accendo Markets, "has not impressed investors and shows a lack of confidence in Chidwick and the company going forward." Moreover, analysts have highlighted the pressure on earnings from many sources going into the future.

Glencore, down 2.8%. The company reported that own-sourced copper production was down 12% on the second half of 2013 due to lower head grades caused by mine sequencing at Collahuasi and Antamina and planned maintenance shut downs at its Collahuasi, Mount Isa and Mopani mines. In addition, own-sourced zinc production was 650,400 tonnes, down 11% on the year, primarily due to Glencore's Perseverance and Brunswick mines having depleted their reserves in June 2013. Production was broadly flat compared with the second half of 2013, as a ramp up at the Perkoa mine largely offset mine sequencing lower grades at Antamina and some opportunistic favouring of third party feed at Kazzinc.

BT Group, down 1.3%, IMI, down 1.2%, Diageo, down 1.1%, Meggitt, down 1%, GKN, down 0.8%, Standard Chartered, down 0.7%, Schroders, down 0.5%, and Ashtead Group, down 0.4%. The companies are among the fallers in the blue-chip index after going ex-dividend, meaning new buyers no longer qualify for the latest dividend payouts.

AstraZeneca, down 0.7%. The company was amongst those whose shares went ex-dividend. It also was subject to a price target cut by Societe Generale from 3,740p to 3,700p.
-------
FTSE 250 - WINNERS
-------
Evraz, up 2.3%. The Russian steel company said it has signed an agreement to sell a 34% stake in Evraz Highveld Steel and Vanadium to Macrovest 147 Proprietary Ltd for ZAR289 million, or about USD27 million. "We have analysed various options for the further development of Highveld and decided to introduce a strong local partner, who we believe will add significant value and expertise in developing our South African asset in a challenging market," said EVRAZ Chief Executive Alexander Frolov in a statement. Evraz will keep a 51% stake in South Africa-based Highveld, and said it will continue to focus on improving the operating efficiency of the unit and undertaking initiatives that will boost its profit. Evraz also said Wednesday it has signed a USD425 million syndicated pre-export credit facility with a syndicate of banks to refinance its existing debt pile.
-------
FTSE 250 - LOSERS
-------
EnQuest, down 5.8%. The oil and gas company has posted a rise in pretax profit in the first half on Wednesday though it warned of further delays to the Alma/Galia development in the North Sea and said its cost of sales also jumped higher in the period. Pretax profit for the company rose 3.6% to USD284.0 million from USD274.0 million a year earlier coming on the back of an 11% rise in revenue to USD503.8 million from USD455.9 million last year. But its cost of sales rose to USD339.5 million in the period from USD280.9 million in 2013. On Alma/Galia, the company said progress has been made on the floating production, storage and offloading unit for the development, but warned sail away of shipments is now weather-dependent.

Direct Line Insurance Group, down 4%. The motor insurer is one of the leading losers in the mid-cap index following the trend of the whole sector. Shore Capital notes that regulatory clouds still surround the industry and that UK households are being provided no respite from an income squeeze, as evidenced by the most recent wage data.

Countrywide, down 3.7%, Greene King, down 2.4%, Vesuvius, down 1.1%, Man Group, down 1%, and MoneySupermarket.com Group, down 0.8%. The companies are among the fallers in the FTSE 250 after going ex-dividend.

CSR, down 2.7%. The company was amongst those whose shares went ex-dividend and also has been downgraded by Jefferies to Hold from Buy with a price target of 569p, down from 679p.

Michael Page International, down 2.2%. The recruitment company reported higher profit and revenue for the first half of the year as the economic recovery drove improved hiring in its major markets, although its overseas earnings took a big hit from the strength of sterling. The company reported a pretax profit of GBP35.6 million for the six months to June 30, up from GBP32.0 million a year earlier, as revenue rose to GBP512.2 million, from GBP503.2 million, and it felt the benefit of cost savings and efficiency programmes it undertook last year. However, the currency hit meant revenue growth was just 1.8%, compared with 8.3% growth at constant currencies, while its operating profit grew 11%, compared with 21.4% at constant currencies.
-------
AIM ALL-SHARE - WINNERS
-------
Getech Group, up 12%. The company expressed confidence in a "substantially improved" performance in its new financial year, on the back of a strong second half of the recently completed year and the signing of contracts worth over USD5 million. The company expects to post a pretax profit of GBP1.0 million for the year to end-July, down from GBP2.2 million in the previous year, on revenue of GBP6.6 million, down from GBP8.0 million. Getech said that the first part of the year had seen lower spending across the whole oil and gas exploration sector, However, it had ended the year strongly, as it expected. Getech cited strength in its US gravity data operations, strong demand for its consultancy service, and the completion of its first three years of its Globe platform. The Globe platform, a geographic information system, is expected to produce further sales with a "significant number of commitments" in the second half.

Vipera, up 11%. The mobile financial services company said its Codd & Date Srl subsidiary has executed a contract for the use of its technology by IfItalia, part of the BNP Paribas Group. IfItalia has launched a new mobile service in Italy for financial services called IfiMobile, which uses Vipera's Motif platform. The company said that this takes the Motif platform beyond applications for retail customers. No financial details of the contract were disclosed.

Amara Mining, up 11%. The gold miner reported exceptional drilling results from the Yaoure gold project in Côte d'Ivoire. The company said the latest 15 diamond drill results showed exceptional intercepts, demonstrating high-grade areas in the Yaoure central zone and the presence of mineralisation in 'information gaps'.

Flowgroup, up 7.7%. The energy-efficient technology firm said it has signed a heads of agreement with Mears Group for Mears to provide installation and after-care services for Flowgroup's microCHP boiler. Under the terms of the agreement, Mears will provide nationwide coverage for the installation of the boiler, along with servicing and maintenance. Flowgroup said the inclusion of servicing and installation in the agreement could have the potential to deliver a strong, ongoing revenue stream for the company from the servicing market.

Daisy Group, up 6.9%. The communications company said it has received a preliminary takeover approach from a consortium consisting of Toscafund Asset Management LLP, Penta Capital LLP and Daisy Chief Executive Matthew Riley. The company said it received an approach of 190 pence per share from the consortium July 27. Daisy said that it has convened an independent committee of the board to engage in preliminary discussions with the consortium. Toscafund confirmed in a separate statement Wednesday that the consortium was at the "preliminary stage" of considering a possible cash offer for Daisy.
-------
AIM ALL-SHARE - LOSERS
-------
President Energy, off 24%. The company is the leading faller in the AIM index after it suspended drilling at the Jacaranda-1 well in Paraguay, despite expressing optimism that the results from the well de-risks the remaining two wells in the drilling campaign. President said the Jacaranda-1 well had been drilled to a depth of 4,500 metres, but has now been suspended for re-entry at a later date. It also said that while the well confirmed developed reservoir-quality sand, the carboniferous sandstone was not sealed and hydrocarbons have migrated away.

Hutchinson China MediTech, down 10%. The company said that an independent data safety and monitoring committee had recommended that a Phase III trial of its HMPL-004 treatment for ulcerative colitis be terminated following an interim analysis of the trial. The trial is being conducted by Nutrition Science Partners, Hutchinson's joint venture with Nestlé Health Science SA. The independent committee evaluated the data of two doses of the compound compared to a placebo. Hutchinson said that no meaningful safety signals or risks for patients were identified, and further analysis and review of the data will be conducted.
-------
By Neil Thakrar; neilthakrar@alliancenews.com

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
24 Jun 2024 12:20

Hutchmed partner gets European approval for fruqintinib

(Sharecast News) - Hutchmed China announced on Monday that its partner Takeda has received approval from the European Commission for 'Fruzaqla', or fruquintinib, as a monotherapy for adult patients with metastatic colorectal cancer (CRC).

Read more
24 Jun 2024 10:00

IN BRIEF: Hutchmed China notes Takeda obtains EU approval for Fruzaqla

Hutchmed (China) Ltd - Hong Kong-headquartered biopharmaceutical company - Notes that Takeda Pharmaceuticals Co Ltd received a notification from the European Commission that it has approved Fruzaqla, alias fruquintinib, as a monotherapy for adults with metastatic colorectoral cancer who have been previously treated with available standard therapies. Takeda has the exclusive worldwide license to develop, commercialise and manufacture fruquintinib outside of mainland China.

Read more
17 Jun 2024 10:32

Hutchmed celebrates "promising" results for sovleplenib in China

(Alliance News) - Hutchmed (China) Ltd on Monday said its phase 3 trial of sovleplenib showed "consistent benefits" in adults with autoimmune disorder primary immune thrombocytopenia or ITP.

Read more
17 Jun 2024 09:28

Hutchmed publishes positive sovleplenib trial results

(Sharecast News) - Hutchmed China announced the publication of positive results from its phase three 'ESLIM-01' trial of sovleplenib in the Lancet Haematology.

Read more
7 Jun 2024 18:13

IN BRIEF: Hutchmed (China) begins trial of menin inhibitor HMPL-506

Hutchmed (China) Ltd - Hong Kong-headquartered biopharmaceutical company - Says that it has initiated Phase I clinical trial of its menin inhibitor HMPL-506 in patients with hematological malignancies in China. The first patient received their first dose on May 31. "This is a Phase I, multicenter, open-label clinical study to evaluate the safety, pharmacokinetics and efficacy of HMPL-506 in patients with hematological malignancies. The study is divided into two phases, a dose escalation phase and a dose expansion phase. The study is expected to enroll at least 60 patients," Hutchmed says. HMPL-506 is a novel, investigational, selective small molecule inhibitor for oral administration targeting the menin protein, it explains.

Read more
17 May 2024 17:58

IN BRIEF: Hutchmed China Simon To leaves role, succeeded by Dan Eldar

Hutchmed (China) Ltd - Hong Kong-headquartered biopharmaceutical company - Chair Simon To retires from his role as chair, succeeded by Dan Eldar, effective immediately. Former chair To agrees to serve as strategic advisor to Hutchmed and will continue to contribute to the company "on significant matters". In a separate release, the company highlights Sovleplenib phase 3 data in adult patients with primary immune thrombocytopenia who have received at least one prior line of standard therapy. ITP is an autoimmune disease characterised by a low platelet count, purpura, and hemorrhagic episodes caused by antiplatelet autoantibodies. Hutchmed will present the data in mid-June in Madrid.

Read more
14 May 2024 14:33

Hutchmed announces trials of HMPL-306 and Surufatinib cancer therapies

(Alliance News) - Hutchmed (China) Ltd on Tuesday announced upcoming trials for two of its pipeline cancer treatments, both of which it believes could fill significant clinical gaps.

Read more
14 May 2024 11:42

Hutchmed China launches two cancer treatment trials

(Sharecast News) - Hutchmed China announced the start of two significant clinical trials on Tuesday, aimed at addressing critical unmet needs in cancer treatment.

Read more
3 May 2024 13:37

UK shareholder meetings calendar - next 7 days

Monday 6 May 
no events scheduled 
Tuesday 7 May 
Caledonia Mining Corp PLCAGM
CPPGroup PLCAGM
Just Group PLCAGM
Macfarlane Group PLC AGM
Plus500 LtdAGM
Supernova Digital Assets PLCAGM
Wednesday 8 May 
Airea PLCAGM
Antofagasta PLCAGM
Aston Martin Lagonda Global Holdings PLCAGM
Deltex Medical Group PLCAGM
Direct Line Insurance Group PLCAGM
Fidelity European Trust PLCAGM
Haleon PLCAGM
Jardine Matheson PLCAGM
JZ Capital Partners LtdEGM re investing in a secondary fund
Oscillate PLCAGM
Pershing Square Holdings LtdAGM
Rentokil Initial PLCAGM
WPP PLCAGM
Thursday 9 May 
Ascential PLCAGM
BAE Systems PLCAGM
Balfour Beatty PLCAGM
Barclays PLCAGM
CAB Payments Holdings PLCAGM
Catenai PLCGM re convertible loan note
Clarkson PLCAGM
FBD Holdings PLCAGM
Genel Energy plcAGM
Gym Group PLCAGM
Harbour Energy PLCAGM
Hiscox LtdAGM
IMI PLCAGM
Inchcape PLCAGM
Indivior PLCAGM
John Wood Group PLCAGM
Jupiter Fund Management PLCAGM
Logistics Development Group PLCAGM
Man Group PLCAGM
Morgan Advanced Materials PLCAGM
OSB Group PLCAGM
Public Policy Holding Co IncAGM
Rathbones Group PLCAGM
RM PLCAGM
Spire Healthcare Group PLCAGM
Synthomer PLCAGM
Uniphar PLCAGM
Friday 10 May 
Cairn Homes PLCAGM
Derwent London PLCAGM
Diversified Energy Co PLCAGM
Hutchmed China LtdAGM
Irish Residential Properties REIT PLCAGM
Kenmare Resources PLCAGM
Rightmove PLCAGM
Serinus Energy PLCAGM
Standard Chartered PLCAGM
Wheaton Precious Metals CorpAGM
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
26 Apr 2024 16:09

Hutchmed notes CHMP's positive opinion for fruiquintinib approval

(Alliance News) - Hutchmed (China) Ltd on Friday said that its partner Takeda Pharmaceutical Co Ltd has been notified that the Committee for Medicinal Products for Human Use of the European Medicines Agency recommends approval for fruquintinib.

Read more
5 Apr 2024 11:54

Hutchmed China to make several presentations at cancer research meeting

(Sharecast News) - Hutchmed China announced the upcoming presentation of new and updated data from various studies featuring compounds it had discovered on Friday, at the American Association of Cancer Research (AACR) annual meeting from 5 to 10 April in San Diego, California.

Read more
2 Apr 2024 12:11

Hutchmed endometrial cancer treatment gets priority review in China

(Sharecast News) - Hutchmed China announced the acceptance and granting of priority review by the China National Medical Products Administration (NMPA) for a new drug application combining fruquintinib and sintilimab for the treatment of advanced endometrial cancer on Tuesday.

Read more
2 Apr 2024 10:32

Hutchmed endometrial cancer treatment application accepted for review

(Alliance News) - Hutchmed (China) Ltd on Tuesday jointly announced with Innovent Biologics that their new drug application for the combined fruquintinib and sintilimab treatment for endometrial cancer has been granted priority review by the China National Medical Products Administration.

Read more
2 Apr 2024 08:05

LONDON BRIEFING: HSBC in special payout on Canada sale; Astra FDA win

(Alliance News) - London's FTSE 100 traded higher on Tuesday following the long weekend, as investors react to US data, and look ahead to manufacturing sector readings from Europe later.

Read more
28 Mar 2024 13:02

Hutchmed cancer treatment indication accepted for review in China

(Sharecast News) - Hutchmed China announced a significant milestone in its cancer treatment work on Thursday, with the supplemental new drug application (sNDA) for savolitinib had been accepted for review by the China National Medical Products Administration (NMPA).

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.